Bigumal

Bigumal is an antimalarial drug from the group of 8-aminoquinoline derivatives. International nonproprietary name - Proguanil.

Proguanil has antimalarial activity against malarial plasmodia - P. falciparum, P. vivax, P. ovale, P. malariae. It has a gasontotropic and tissue-specific effect. It disrupts the biosynthesis of parasite enzymes, which leads to the death of malarial plasmodia in red blood cells and the liver.

Proguanil is used for the treatment and prevention of all types of malaria caused by pathogens sensitive to the drug. Prescribed internally. The recommended prophylactic dose for adults is 100 mg once a week. The course of treatment for acute malaria is 100 mg once a day for 3 days.

Bigumal is available in tablets of 0.1 g. The drug is well tolerated, side effects are rare. Allergic reactions and gastrointestinal disorders are possible. Contraindicated in patients with glucose-6-phosphate dehydrogenase deficiency.